CoChat

Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β‐amyloid

Open access
Maki, Takakuni, Okamoto, Yoko, Carare, Roxana O., Hase, Yoshiki, Hattori, Yorito, Hawkes, Cheryl A., Saito, Satoshi, Yamamoto, Yumi, Terasaki, Yasukazu, Ishibashi‐Ueda, Hatsue, Taguchi, Akihiko, Takahashi, Ryosuke, Miyakawa, Taihei, Kalaria, Raj N., Lo, Eng H., Arai, Ken, Ihara, Masafumi · 2014 · Annals of Clinical and Translational Neurology
Cited by 99

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Objective: Brain amyloidosis is a key feature of Alzheimer's disease (AD). It also incorporates cerebrovascular amyloid β (Aβ) in the form of cerebral amyloid angiopathy (CAA) involving neurovascular dysfunction. We have recently shown by retrospective analysis that patients with mild cognitive impairment receiving a vasoactive drug cilostazol, a selective inhibitor of phosphodiesterase (PDE) III, exhibit significantly reduced cognitive decline. Here, we tested whether cilostazol protects against the disruption of the neurovascular unit and facilitates the arterial pulsation‐driven perivascular drainage of Aβ in AD/CAA. Methods: We explored the expression of PDE III in postmortem human brain tissue followed by a series of experiments examining the effects of cilostazol on Aβ metabolism in transgenic mice (Tg‐SwDI mice) as a model of cerebrovascular β‐amyloidosis, as well as cultured neurons. Results: We established that PDE III is abnormally upregulated in cerebral blood vessels of AD and CAA subjects and closely correlates with vascular amyloid burden. Furthermore, we demonstrated that cilostazol treatment maintained cerebral hyperemic and vasodilative responses to hypercapnia and acetylcholine, suppressed degeneration of pericytes and vascular smooth muscle cells, promoted perivascular drainage of soluble fluorescent Aβ 1‐40, and rescued cognitive deficits in Tg‐SwDI mice. Although cilostazol decreased endogenous Aβ production in cultured neurons, C‐terminal fragment of amyloid precursor protein expression was not altered in cilostazol‐treated Tg‐SwDI mice. Interpretation: The predominant action of cilostazol on Aβ metabolism is likely to facilitate Aβ clearance due to the sustained cerebrovascular function in vivo. Our findings mechanistically demonstrate that cilostazol is a promising therapeutic approach for AD and CAA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acn3.79

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

Metadata

Authors
Maki, T., Okamoto, Y., Carare, R. O., Hase, Y., Hattori, Y., Hawkes, C. A., Saito, S., Yamamoto, Y., Terasaki, Y., Ishibashi‐Ueda, H., Taguchi, A., Takahashi, R., Miyakawa, T., Kalaria, R. N., Lo, E. H., Arai, K., & Ihara, M.
Venue
Annals of Clinical and Translational Neurology
Publisher
Wiley
Published
2014-07-08
Volume
1
Issue
8
Pages
519-533
ISSN
2328-9503 (ISSN-L)
OpenAlex
W2044546031
Cited by
99
References
21
FWCI
4.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.